Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
Clinical trial NCT03382977 · TERMINATED
Trial details
- NCT number
- NCT03382977
- Sponsor
- VBI Vaccines Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-06
- Primary completion
- 2025-07-30
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.